Complete Response of Pazopanib Treatment in Cystic Renal Cell Carcinoma with Liver Metastasis Patient: A Case Report
DOI:
https://doi.org/10.59784/glosains.v7i2.749Keywords:
cystic renal cell carcinoma (CRCC), nephrectomy, pazopanibAbstract
Background: Cystic renal cell carcinoma (CRCC) is a rare renal malignancy. Complete radiologic response of metastatic CRCC with liver metastasis following pazopanib therapy is rarely reported. This case highlights a successful treatment outcome.
Objective: To describe the clinical course, diagnostic workup, treatment strategy, and complete radiologic response in a patient with cystic renal cell carcinoma (CRCC) presenting with liver metastasis and treated with pazopanib.
Methods: This case report describes a single patient diagnosed with cystic renal cell carcinoma with hepatic metastasis. Clinical, laboratory, imaging, including computed tomography (CT) and magnetic resonance imaging (MRI), and histopathologic data were collected and analyzed. The CARE guidelines for case report writing were followed.
Results: A 50-year-old woman presented with a 3-month history of weakness, decreased appetite, weight loss, and persistent anemia (Hb 8 g/dL) that was unresponsive to blood transfusion. Imaging studies revealed a large left cystic renal mass measuring 13.6 × 11.8 × 11 cm, with suspected liver metastasis in segment VIII. Following cytoreductive nephrectomy, histopathologic examination confirmed papillary renal cell carcinoma, Fuhrman grade 2, leading to a diagnosis of cystic renal cell carcinoma with hepatic metastasis. The patient subsequently received pazopanib 400 mg twice daily. After 10 months of treatment, complete radiologic disappearance of the liver metastasis was achieved.
Conclusion: This case demonstrates that pazopanib therapy, in combination with cytoreductive nephrectomy, can achieve a complete radiologic response of hepatic metastasis in CRCC. Pazopanib represents a viable and well-tolerated targeted therapy option for metastatic CRCC, warranting further clinical investigation.
References
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., & Li, J. (2014). A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 5(1), 3887. https://doi.org/10.1016/j.urology.2012.11.030
Bellin, M.-F., Valente, C., Bekdache, O., Maxwell, F., Balasa, C., Savignac, A., & Meyrignac, O. (2024). Update on renal cell carcinoma diagnosis with novel imaging approaches. Cancers, 16(10), 1926. https://doi.org/10.3390/cancers16101926
Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., Gore, J. L., Sun, M., Wood, C., & Russo, P. (2019). Epidemiology of renal cell carcinoma. European Urology, 75(1), 74–84. https://doi.org/10.1016/j.eururo.2018.08.036
Darwish, O. M., Kapur, P., Youssef, R. F., Bagrodia, A., Belsante, M., Alhalabi, F., Sagalowsky, A. I., Lotan, Y., & Margulis, V. (2013). Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology, 81(3), 581–586. https://doi.org/10.1016/j.urology.2012.11.030
El Hage, M., Su, Z., & Linnebacher, M. (2025). Addressing challenges in targeted therapy for metastatic colorectal cancer. Cancers, 17(7), 1098. https://doi.org/10.3390/cancers17071098
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017). Renal cell carcinoma. Nature Reviews Disease Primers, 3(1), 17009. https://doi.org/10.1038/nrdp.2017.9
Ismail, M. F. (2024). Comparing the Efficacy and Side Effect Profiles of Pazopanib and Sunitinib in the Treatment of Advanced Renal Cell Carcinoma: A Narrative Literature Review. Choice, 8, 9.
Kalita, N. P., Das, A., Dowerah, S., Nath, S. J., & Das, J. (2023). Renal Cell Carcinoma Grossly Presenting as Cystic Lesions: A Series of Four Cases. Journal of Clinical & Diagnostic Research, 17(9). https://doi.org/10.7860/JCDR/2023/63590.18480
Kaur, R., Juneja, M., & Mandal, A. K. (2020). An overview of non-invasive imaging modalities for diagnosis of solid and cystic renal lesions. Medical & Biological Engineering & Computing, 58(1), 1–24. https://doi.org/10.1007/s11517-019-02049-z
Kuthi, L. (2020). Clinicopathological Features of the Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification. University of Szeged (Hungary).
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bedke, J., Capitanio, U., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., & Hora, M. (2022). European Association of Urology guidelines on renal cell carcinoma: the 2022 update. European Urology, 82(4), 399–410. https://doi.org/10.1016/j.eururo.2022.03.006
Low, G., Huang, G., Fu, W., Moloo, Z., & Girgis, S. (2016). Review of renal cell carcinoma and its common subtypes in radiology. World Journal of Radiology, 8(5), 484.
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., & Merchan, J. R. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), 722–731.
Nabi, S., Kessler, E. R., Bernard, B., Flaig, T. W., & Lam, E. T. (2018). Renal cell carcinoma: a review of biology and pathophysiology. F1000Research, 7, 307. https://doi.org/10.12688/f1000research.13179.1
Ongaro, L., Amodeo, A., Crestani, A., Di Gianfrancesco, L., Giannarini, G., Garaffa, G., Simonato, A., Porreca, A., Pavan, N., & Claps, F. (2026). Renal Cell Carcinoma: Integrating Histology, Multiomics, and Targeted Therapeutic Strategies. In Molecular Precision Medicine in Cancer (pp. 151–186). Springer.
Sharma, R., Kadife, E., Myers, M., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2021). Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental & Clinical Cancer Research, 40(1), 186. https://doi.org/10.1186/s13046-021-01961-3
Skenderi, F. (2021). Clinico pathological and molecular characterization of tubulocystic variants of renal tumors. Sveučilište u Zagrebu, Sveučilište u Zagrebu, Medicinski fakultet.
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., & Kavina, A. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology, 28(6), 1061–1068.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Yurmazov, Z. A., Usynin, Е. A., Spirina, L. V, Kondakova, I. V, & Slonimskaya, Е. M. (2016). Prognostic Significance Of Expression Of Transcription Factors, Vegf Growth Factor And Its Receptor, M-Tor Protein Kinase And The Activity Of Intracellular Proteinases In Patients With Disseminated Renal Cell Carcinoma. Siberian Journal of Oncology, 1(5), 44–50.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhammad Firas Balafif, Kurnia Penta Seputra, Medianto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
